Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
06:21pm, Sunday, 18'th Dec 2022
Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
Expect heavy market selling early next year, says Worth Charting's Carter Worth
03:01pm, Monday, 05'th Dec 2022
Carter Worth, Worth Charting CEO, joins 'The Exchange' to give the technical take on Eli Lilly and XBI.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:32am, Wednesday, 23'rd Nov 2022
Smart Beta ETF report for XBI
XBI: Mid-Term Election Results Are Good For Biotech Stocks
08:53am, Thursday, 10'th Nov 2022
The drug-price reform focus of Congress affects biopharma stock prices. The likelihood that Republicans will control at least the House, is good for biotech stocks.
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
09:02am, Wednesday, 09'th Nov 2022
Biotech earnings have come in upbeat in the third quarter.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:34am, Monday, 07'th Nov 2022
Sector ETF report for XBI
Biotech And XBI: The Bottom Is In
03:19am, Tuesday, 01'st Nov 2022
Today, we take a look at the SPDR S&P Biotech ETF, a widely diversified ETF comprised of myriad small and midcap biotech stocks. This ETF appears to be set up to outperform in the quarters ahead for s
XBI vs IBB: what's a better way to play the biotech space?
04:49pm, Sunday, 30'th Oct 2022
Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.
XBI: A Classic 'Glass Half Full Or Half Empty' Story
03:08pm, Sunday, 30'th Oct 2022
XBI is down 26% since January and down 33% since the same time last year following a correction fueled by pandemic-era investment. This year's drawdown of XBI provides opportunity for gains due to fun
Requisite's Bryn Talkington discusses whys she liked XBI over IBB in biotech
06:26pm, Friday, 28'th Oct 2022
Bryn Talkington, Requisite Capital, joins 'Closing Bell: Overtime' to discuss the biotech sector.
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
05:55am, Friday, 21'st Oct 2022
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.
Bear Market Rally in the Cards? Top-Ranked Low P/E ETFs to Tap
09:02am, Wednesday, 12'th Oct 2022
The current pullback in the S&P 500 is now the longest from peak to trough since the March 2009 low at 269 days and counting, according to research from Compound Capital Advisors, as quoted on Yahoo F
My 3 Biggest Stock Market Predictions for October
06:15am, Tuesday, 11'th Oct 2022
Now's not the best time to bet the farm on anything other than more uncertainty coming up.
Top-Ranked ETFs That Beat the Market in Q3
11:17am, Tuesday, 04'th Oct 2022
After logging the best month since July 2020, the Wall Street rally fizzled in August on aggressive Fed rate hike speculation. This has pushed the major indices to end the quarter with losses.
On CNBC's “The Final Call,” Carter Worth said he liked biotech. He named SPDR S&P Biotech ETF (ARCA: XBI) hit a low on May 11 but “the S&P hasn't bottomed yet.
